Orexigen™ Therapeutics, Inc., has announced positive results at the 24 week primary endpoint of its Phase IIb trial of Empatic™, formerly known as Excalia™. Empatic™ is one of two promising new drugs Orexigen™ is developing to fight obesity. Using six treatment arms in the trial, Empatic™ showed statistically significant weight loss against placebo in all cases.
Using a combination of zonisamide SR paired with bupropion SR, the discontinuation rate of 14% was significantly lower than previous results which used an immediate release version of zonisamide.
Rates of adverse effects which included headache, nausea, insomnia, anxiety or dry mouth, were consistent with the effects expected with the individual drugs.
Information in this post came from an Orexigen Press release. You can view the entire release at http://ir.orexigen.com/releasedetail.cfm?ReleaseID=256033.
Technorati Tags: Empatic™ Ecalia™ Weight Loss Pills Weight Loss DrugsObesityEmpatic™
Friday, October 5, 2007
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment